The lack of recent posts here has not been due to lack of interest or work in the main interest areas I’ve written about here: oncology, diagnostics, genomics, etc. Rather, a new adventure, Hepatx Corporation (www.hepatx.com), has demanded all of the extra bandwidth I have. As the title of this site (Biology, Etc.) suggests, topics that might be discussed can range across the field of biology. So, I’m happy to share that I will broaden the range of topics to include stem cells, regenerative medicine, liver disease, and entrepreneurship. I’m sure other topics will be added, as needed.
A bit about Hepatx and what we are trying to accomplish. As it turns out, there is a very large need for new therapeutic options in liver disease. Alcohol abuse and various forms of viral hepatitis have exacted the largest toll, however, concern is rising that an epidemic of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is underway, which will increase demand for treatments for scarred and failing livers. Literally hundreds of thousands of people in the U.S. are affected at a cost of multiple billions of dollars. Still the only treatment that works is transplantation. We started Hepatx to address this problem with new therapies that can improve liver function for these patients.
I will continue to post discussion of oncology and diagnostics, since this is still an area of active interest. Hopefully the reader will continue to enjoy this, as well as the broadened discussion around novel treatments for liver disease.